Log In

 

Company Name : Ferring Pharmaceuticals

Tuesday, February 14, 2017 2:29AM IST (8:59PM GMT)

(BW)(FERRING-PHARMACEUTICALS)

Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement


Saint-Prex, Switzerland

Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.

 

Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee. Execution of a definitive agreement would entitle Foresee to additional payments including upfront, milestones and royalties based on net sales of the product(s) commercialized by Ferring.

 

“We have been impressed with Foresee’s achievements to date and we see value in its SIF platform technology,” said Alan S. Harris, Senior Vice President, R&D Executive Office at Ferring. “The technical barriers Foresee has overcome in developing stable, formulated peptides in solution for controlled release therapy for three and six-month durations of action after a single injection are quite significant, and this gives us much confidence in the potential of the SIF platform applied to complex peptide drug substances. We are enthusiastic about this new collaboration.”

 

“We are excited about entering into this collaboration with Ferring, a global specialty pharmaceutical company with a long-standing history of innovation in the area of injectable therapeutic peptides and the application of novel formulations and delivery technologies to generate differentiated product profiles,” said Dr. Ben Chien, Chairman and CEO of Foresee. “We are confident that our SIF platform will provide significant value to Ferring’s R&D product portfolio and very much look forward to working with them on this project.”

 

ENDS

 

About Ferring Pharmaceuticals

 

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

 

About Foresee Pharmaceuticals

 

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery platform and derived drug products targeting large specialty markets, and its transformative early stage preclinical and clinical NCE programs targeting inflammatory & fibrotic diseases and other disease areas with high unmet needs. Foresee has a product portfolio including late stage and early stage programs such as FP-001, a stable, premixed, prefilled version of leuprolide depot for injection, which has recently successfully completed a global Phase III Registration Study and FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, which is currently completing a Phase 1 study.

 

 

 

 


Click here for Media Contact Details
CONTACTS : Ferring Pharmaceuticals Lindsey Rodger Tel. +41 58 451 40 23 lindsey.rodger@ferring.com or Foresee Pharmaceuticals Mathieu Boudreau, Ph.D. Tel. +1 514 806 9036 mathieu.boudreau@foreseepharma.com

More News from Ferring Pharmaceuticals

10/10/2017 8:05PM

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device

Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.   This ...

03/10/2017 9:10AM

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer

Ferring Pharmaceuticals announced that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately.   He will be responsible for Global Medical Affairs, ...

06/07/2017 11:50AM

Ferring Appoints Lars Peter Brunse to Executive Board

Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective ...

Similar News

20/10/2017 2:30PM

उद्यमशीलता के लिए गोल्डमैन सैक्स ने किया आरएक्सएडवांस को सम्मानित

गोल्डमैन सैक्स (एनवाईएसई : जीएस) ने सैंटा बारबरा, कैलिफ़ोर्निया में अपने बिल्डर्स + इनोवेटर्स समिट में आरएक्सएडवांस के प्रेसिडेंट और सीईओ रवि इका को वर्ष 2017 के सर्वाधिक आकर्षक उद्यमी के रूप में सम्मानित ...

No Image

20/10/2017 1:46PM

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Celgene Corporation (NASDAQ:CELG) announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in relapsing multiple ...